Zymeworks (ZYME) Stock Analysis & AI Equity Report
Zymeworks (ZYME) overview
Zymeworks (ZYME) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 106m and operating profit of USD -92.5m; the year-end share price was 26.33 USD and market capitalisation was USD 1,965m. Zymeworks is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Zymeworks's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Zymeworks
Zymeworks is a biotechnology company managing licensed healthcare assets and developing antibody-based therapeutics for cancer, inflammation, and autoimmune disease. Its portfolio includes partnered products and candidates such as Ziihera and pasritamig. The company uses multispecific antibody and antibody-drug conjugate technology platforms, and works with partners on development and commercialization through arrangements that can include milestone payments and royalties.
Generate the Zymeworks report
Zymeworks is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Zymeworks and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Zymeworks
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.